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Epigenome-wide DNA methylation proﬁling in
Progressive Supranuclear Palsy reveals major
changes at DLX1
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Genetic, epigenetic, and environmental factors contribute to the multifactorial disorder
progressive supranuclear palsy (PSP). Here, we study epigenetic changes by genome-wide
analysis of DNA from postmortem tissue of forebrains of patients and controls and detect
signiﬁcant (P < 0.05) methylation differences at 717 CpG sites in PSP vs. controls. Four-
hundred ﬁfty-one of these sites are associated with protein-coding genes. While differential
methylation only affects a few sites in most genes, DLX1 is hypermethylated at multiple sites.
Expression of an antisense transcript of DLX1, DLX1AS, is reduced in PSP brains. The amount
of DLX1 protein is increased in gray matter of PSP forebrains. Pathway analysis suggests that
DLX1 inﬂuences MAPT-encoded Tau protein. In a cell system, overexpression of DLX1 results
in downregulation of MAPT while overexpression of DLX1AS causes upregulation of MAPT.
Our observations suggest that altered DLX1 methylation and expression contribute to
pathogenesis of PSP by inﬂuencing MAPT.
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Progressive supranuclear palsy (PSP) is a progressive andfatal neurodegenerative disease with a prevalence of 5−7/100,0001,2. Disease onset is usually beyond 60 years of age
and the average survival time is 6–7 years after onset1. Symptoms
include ocular motor dysfunction, postural instability, akinesia,
cognitive dysfunction, and dysphagia, with the latter being the
most frequent cause of death in PSP1,2.
PSP is neuropathologically deﬁned by intracellular aggregation
of the microtubule-associated protein Tau in neuroﬁbrillary
tangles and tufted astrocytes. The aggregates eventually cause
neuronal cell death in the cerebral cortex, diencephalon, brain-
stem, and cerebellar nuclei3.
PSP is a “complex” disorder; genetic, environmental and epi-
genetic modiﬁcations contribute to disease. A variant of the gene
MAPT is the major genetic risk factor in PSP4,5. Variants of the
genes STX6, EIF2AK3, and MOBP also increase the risk of PSP5.
Among environmental factors, advanced age is the best estab-
lished risk factor6. Epigenetic modiﬁcations reported so far in PSP
include aberrant DNA methylation at the MAPT locus7–9 and
miRNA dysregulation10,11.
In order to learn more about the possible relevance of epige-
netic changes in PSP we set out to study epigenetic alterations at
the DNA level in prefrontal lobe tissue of PSP patients. We
describe signiﬁcant DNA methylation differences between
patients and controls at many CpG sites, amounting to 451
protein-coding genes. While methylation differences only affect
one or a few sites at most genes, highly signiﬁcant ( ≥ 5%)
hypermethylation is found at multiple sites associated with the
gene DLX1. Functional analyses of both DLX1 and its antisense
transcript DLX1AS are consistent with an important role of DLX1
in the pathogenesis of PSP.
Results
Differentially methylated sites in PSP. The genome-wide DNA
methylation patterns of 94 PSP patients (72 ± 5.3 years; 57% male,
43% female) were compared to 71 controls (76 ± 7.9 years; 67%
male, 33% female) without neurological or psychiatric diseases
(Supplementary Data 1). We studied prefrontal lobe tissue since it
is consistently pathologically damaged in PSP, but less so than
other brain regions3. We estimated the amount of neuronal and
non-neuronal cells in our samples, as described by Guintivano
et al.12. The percentage of neurons in PSP patients (median 36.1%
of cells) did not signiﬁcantly differ from the proportion of neu-
ronal cells in controls (median 38.0% of cells; Wilcoxon test, P=
0.31) (Supplementary Fig. 1). Thus, we detected disease-speciﬁc
alterations and minimized a potential bias by a massive change in
regional cellular composition due to severe neurodegeneration
and gliosis.
Methylation differences at CpG sites between patients and
controls were analyzed on 450 K BeadChips13 applying a linear
regression model with age, sex, and non-neuronal cell content as
covariates at a Benjamini-Hochberg14 corrected level of sig-
niﬁcance of P < 0.05. Signiﬁcant CpGs previously shown to be
inﬂuenced by genetic variants (mQTLs) in adult prefrontal
cortex15 were not included in further analyses. However, only
three CpGs were found to match this criterion, i.e., cg01378667,
cg03325535, cg10318222 in the promoter region of GABRA5, all
of which are associated in cis with rs7496866 located in the same
region. An inﬂuence of presently unknown genetic variants on
the methylation pattern cannot be excluded. It is also not possible
to correct for environmental factors such as individual medica-
tions and/or accompanying neurological diseases that might
affect DNA methylation in the forebrain.
After these corrections, signiﬁcant methylation differences
were detected at 717 sites (627 hyper-, 90 hypomethylated). Mean
differences of ≥ 5% were found at 38 of these sites (34 hyper-, 4
hypomethylated) (Fig. 1a and Supplementary Data 2). Of the
hypomethylated sites, 70% were associated with protein-coding
genes, 4% with genes for non-coding RNAs (miRNAs, lncRNAs,
etc.), and 26% were located beyond 1.5 kb of genes. The respective
percentages for hypermethylated genes were 62, 3.5, and 34.5%
(Fig. 1b).
The percentage of hypomethylated CpG sites within gene
bodies was 40% for hypo- and 28% for hypermethylated sites
(Fig. 1c). Twelve percent of hypo- and 8% of hypermethylated
CpG sites were located within 5´UTRs (Fig. 1c). Seven percent
hypo- and 2% hypermethylated sites were within the ﬁrst exons of
the respective genes.
Among sites hypomethylated in patients 44% were CpG islands
and among hypermethylated sites 25% represented CpG islands.
Thirty-four percent CpG sites were isolated (“open sea”13) and
31% of hypermethylated sites were in “open sea” regions. The
percentages of hypomethylated CpG sites in “shelves” (2–4 kb
from CpG island) was 6%, and that in “shores” (up to 2 kb from a
CpG island13) was 17%. The corresponding percentages for
hypermethylated sites are 8 and 36% (Fig. 1d).
Chromosomal location of differentially methylated genes.
Figure 2 depicts the 375 genes with signiﬁcant methylation dif-
ferences between patients and controls and highlights the ten
genes with differences ≥ 5% (see also Supplementary Data 2).
Eight of these genes are hyper- and two are hypomethylated.
In order to check validity of the BeadChip-based primary
results we analyzed the methylation status at selected loci by
pyrosequencing of bisulﬁte-converted DNA of the same samples.
This conﬁrmed the methylation differences in a representative
subset of six genes, i.e., DLX1/DLX1AS, DLX2, METAP1D,
SLC15A3, SLIT1, and TRRAP (Fig. 3c and Supplementary Fig. 2).
No signiﬁcant differential methylation of MAPT. Analysis of
the region 17q21.31 that spans 1.6 Mb (43,470,000 to 45,061,000
on chromosome 17) and includes MAPT revealed nominally
signiﬁcant methylation differences at 11 sites. However, the
ﬁndings were not signiﬁcant after correction for multiple testing.
The smallest P-value corrected for multiple testing within MAPT
was 0.0578 at chr17:44026659 (Supplementary Data 3).
Pronounced hypermethylation of DLX1. Differential methyla-
tion of ≥ 5% was only detected at a few CpG sites in a small
number of genes in PSP (Fig. 2 and Supplementary Data 2). Most
pronounced hypermethylation was detected at a region of chro-
mosome 2 that includes the gene DLX1 (Distal-Less Homeobox
1). Many sites of DLX1, mainly within its 3´UTR, were hyper-
methylated by ≥ 5%, as shown in a representative heat-map of
11 sites (Fig. 3a).
The DLX1 gene is composed of three exons16. Greatest
methylation differences were found at a CpG island (i.e., a
genomic region of > 200 bp with a CG content of > 50% and an
observed/expected CpG ratio of > 60%) in the 3´UTR, spanning
positions 172952810–172953160 [hg19] on chromosome 2
(Fig. 3b). Pyrosequencing conﬁrmed hypermethylation of nine
CpGs within the CpG island that is located in the 3′UTR of DLX1
(Fig. 3c).
DLX1 transcript. We proceeded to test the level of transcription
of DLX1 by reverse transcription quantitative PCR (RT-qPCR).
Expression of the DLX1 sense transcript did not correlate with
DLX1 methylation and did not signiﬁcantly differ in forebrains
between patients and controls (Fig. 4a).
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Several reports indicate the existence of a Dlx1 antisense
transcript (Dlx1as) in the mouse17–19. We found such a DLX1
antisense (DLX1AS) transcript in cDNA from human brain.
Based on the mouse sequence we predicted a homologous
sequence in human DNA in silico. We used primer walking from
the putative transcription start site 3´ of exon 3 of the sense
transcript to different predicted DLX1AS-exons. We found several
alternatively spliced transcripts of DLX1AS by sequencing
different PCR products and were able to extend longest
transcripts beyond exon 3 of DLX1 (Fig. 3b and Supplementary
Fig. 3). The hypermethylated CpG sites are located in the region
of exon 3 of the DLX1AS gene. A recently described enhancer
region of DLX1 overlaps with exon1 of DLX1AS19,20. For
detection of the antisense transcript a region encoded by DLX1AS
exon1 was used since this exon is part of all splice variants of the
gene (Supplementary Fig. 3).
Transcription of DLX1AS was signiﬁcantly reduced in patients
(P < 0.001) and expression values inversely correlated with the
degree of methylation (P < 0.001, Fig. 4b). Delta Ct values,
calculated according to Pfafﬂ et al.21, shown in Fig. 4b correspond
to a 0.64-fold expression of DLX1AS in PSP as compared
to controls.
Single-cell analysis in healthy human cortex. Dlx1 and Dlx1as
are almost exclusively expressed in neuronal cells in the mouse22
(Supplementary Fig. 4a). Using published RNA-sequencing data
in single cells from healthy human cortex23 we quantiﬁed the
reads of DLX1 and DLX1AS transcripts. Consistent with the
mouse data, we found DLX1 and DLX1AS expression mainly in
neurons (Supplementary Fig. 4b, c). DLX1 was expressed in
26.15%, DLX1AS in 15.39% and both were expressed in 2.31% of
neurons (Supplementary Fig. 4d).
DLX1 protein. Expression of DLX1 was analyzed at the protein
level in total protein extracts of frontal lobes from PSP patients
and controls.
Western blot analysis of eight PSP and eight control forebrains
demonstrated that DLX1 protein levels do not differ between
patients and controls in white matter (Fig. 4c and Supplementary
Fig. 5). In gray matter, however, higher levels of DLX1 protein
were detected in PSP as compared to controls (Fig. 4d and
Supplementary Fig. 6).
The ﬁndings were conﬁrmed by quantitative immunohisto-
chemistry on histological sections of frontal lobes from an
independent set of patients. Densitometry of DLX1-
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Fig. 1 Epigenome-wide methylation analysis. a–d CpG sites hypo- and hypermethylated in n= 94 PSP patients vs. n= 71 controls are displayed on the left
and right panels, respectively. a Number of genomic sites aberrantly methylated at a difference of < 5% and≥ 5% between patients and controls
(Benjamini-Hochberg corrected P < 0.05). b Location of aberrantly methylated sites within protein-coding genes, non-coding genes and intergenic regions.
c Location of aberrantly methylated CpG sites in relation to deﬁned regions of genes (TSS: transcription start site; 5´and 3´UTR: 5′ and 3′ untranslated
region). d Association of aberrantly methylated sites with CpG islands (shores are < 2 kb and shelves are 2–4 kb from a CpG island)
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immunoreactivity did not differ between patients and controls in
white matter (Fig. 4e and Supplementary Fig. 7), but was
signiﬁcantly increased in gray matter of patients (Fig. 4f and
Supplementary Fig. 8).
Overexpression of DLX1 and DLX1AS in Ntera2 and SH-EP
cells. In order to study the function of DLX1 and DLX1AS, we
transfected Ntera2 and SH-EP cells using eukaryotic expression
vector (pcDNA-3.1-TOPO) containing either DLX1 or DLX1AS.
Initial experiments had shown that untreated Ntera2 cells express
less DLX1 than SH-EP cells. DLX1 was overexpressed 3–4-fold in
Ntera2 cells (Fig. 5a) and DLX1AS was overexpressed 100–120-fold
in SH-EP cells (Fig. 5b). We then proceeded to test the expression
of known target genes of DLX1, i.e., GAD124, GAD224, BRN3B25,
GnRH26, and OLIG227. Of these genes GAD1, BRN3B, and OLIG2
were upregulated in cells overexpressing DLX1 (Fig. 5a) and
downregulated in cells overexpressing DLX1AS (Fig. 5b). We also
tested expression of MAPT that had previously been shown to play
an important role in the development of PSP4,5. MAPT expression
was reduced in cells overexpressing DLX1 (Fig. 5a) and increased in
cells overexpressing DLX1AS (Fig. 5b).
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Fig. 2 Circle plot of aberrantly methylated genes. n= 451 CpGs in protein-coding genes and n= 26 CpGs in non-coding RNA genes were found
differentially methylated. After removal of duplicates, i.e., genes with more than one differentially methylated CpG, n= 375 genes show differential
methylation in PSP patients. The two outer circles list the autosomal positions of n= 375 differentially methylated genes (Benjamini-Hochberg corrected
P < 0.05; PSP vs. controls; hypomethylated < 5% (orange),≥ 5% (red); hypermethylated < 5% (light blue),≥ 5% (dark blue)). The intermediate circle
depicts ideograms of the human autosomes head to tail. The inner circle displays the difference between hyper- (blue dots) and hypomethylation (orange/
red dots) in percent at CpG sites in patients vs. controls. The highest degree of hypermethylation was detected at DLX1/DLX1AS (chromosome 2). This plot
was generated according to Hu et al.63
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Knock-down of DLX1 and DLX1AS in human striatal NPC. In
order to test whether a putative down-stream effect of DLX1/
DLX1AS on MAPT also occurs in neural precursor cells (NPC)
derived from human fetal striatum (strNPC) we transfected these
cells with siRNAs that target DLX1 and DLX1AS. As shown in
Fig. 5c knock-down of DLX1 resulted in signiﬁcant upregulation
of MAPT and of DLX1AS. Conversely, knock-down of DLX1AS
resulted in downregulation of MAPT and in upregulation of
DLX1.
We proceeded to test whether DLX1 affects Tau-dependent
viability of strNPCs using the ATP ﬁreﬂy luciferase assay28.
strNPCs overexpressing either 3R- or 4R-Tau were co-transfected
with siRNAs directed against either DLX1 or DLX1AS. As shown
in Fig. 5d, siRNA-mediated knock-down of DLX1 decreased
cellular viability, in particular of cells overexpressing 4R-Tau.
Conversely, knock-down of DLX1AS signiﬁcantly increased
survival of strNPCs (Fig. 5d).
Functional analysis of differentially methylated genes. We
performed in silico functional analyses of 375 different annotated
genes that are represented by 451 (out of a total of 717) differ-
entially methylated CpG sites on the Illumina 450 kb chip (Sup-
plementary Data 2). Applying the Pathway Studio software and
Fisher´s exact test we searched for enrichment of the Gene
Ontology (GO) category “biological process” (Supplementary
Data 4). P-values were corrected for multiple testing according to
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Benjamini and Hochberg14. The top 20 highly signiﬁcantly
enriched categories include important functions pertinent to
DLX1 and DLX2, i.e., “anatomical structure development” (GO
ID 48856), “regulation of signaling” (GO ID 23051), “cell fate
commitment” (GO ID 45165), “positive regulation of transcrip-
tion” (GO ID 45893) and the “cell surface receptor signaling
pathway” (GO ID 7166). All 18 genes assigned to the term “Wnt
signaling pathway” (GO ID 16055), which show a signiﬁcantly
corrected P-value of 6.57 × 10−04 are part of the “cell surface
receptor signaling pathway” (Supplementary Data 4). Particularly
many neuronal functions and pathways are distributed across the
list of signiﬁcantly enriched categories, i.e., “neuron fate com-
mitment” (GO ID 48663), “cerebral cortex GABAergic inter-
neuron fate commitment” (GO ID 28193), and “negative
regulation of neurogenesis” (GO ID 50768) (all of which include
DLX1 and DLX2, Supplementary Data 4).
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Pathway analysis of differentially methylated genes. Pathway
analysis revealed interdependence of several genes found to be
differentially methylated in PSP (Fig. 6 and Supplementary
Data 5). Based on literature mining we propose two main possible
pathways linking DLX1 and MAPT:
(1) Activation of MAPT-encoded Tau protein via the Wnt
signaling pathway: This notion is supported by the ﬁnding
that DLX2 bound to Necdin activates the WNT1 promo-
ter29. In PSP patients, DLX1 and DLX2 are highly ( ≥ 5%)
and the WNT ligand family members WNT10A, WNT8b
are distinctly ( > 3%) hypermethylated. Several additional
differentially methylated genes (methylation differences >
1%) are members of the WNT signaling pathway as well
(Supplementary Data 4). Furthermore, WNT signaling
appears to affect Tau phosphorylation in Alzheimer’s
disease30–32.
(2) Tau phosphorylation via GABA(A) receptors: DLX1, DLX2,
and GABA(A) receptors (encoded by the differentially
methylated genes GABRA5, GABRB3, and GABRD) are
members of the GABAergic interneuron-related network in
humans33. Within this network DLX1/DLX2 regulate
GABA synthesis24. Expression changes of DLX1/DLX2 can
alter activation of GABA(A). GABA(A) receptors in turn
play an important role in Tau phosphorylation34. This
observation is consistent with the notion that Tau may be
affected via DLX1/DLX2 – GABA(A) in PSP.
Interestingly, we also detected two speciﬁc DLX1-binding sites
in the MAPT promoter. One is located 1972-bp upstream of the
TSS. The previously not described DLX1-binding motif (CAT-
AATTAAAAT) was detected using the DiAlign TF program
(Genomatix)35 by utilizing an optimized matrix similarity. It was
found in theMAPT promoter of human and rhesus monkey. At a
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slightly lowered threshold of the optimized matrix similarity of
2% a second DLX1-binding site (TCTAATTTAAGA) was
identiﬁed 550 bp upstream of the human TSS of MAPT. It is
evolutionarily more conserved than the site 1972-bp upstream of
the TSS. Apart from primates (humans and rhesus monkey) it is
also found in other mammalian species such as cow and horse
(Supplementary Fig. 9).
Discussion
This epigenome-wide association study in brains of PSP patients
and controls interrogated > 485,000 CpG sites representing 99%
of RefSeq genes. Signiﬁcant differential DNA methylation
between patients and controls was found at 717 CpG sites. Four-
hundred ﬁfty-one of these sites correspond to 375 annotated
genes. Most methylation differences in PSP were subtle ( < 2% at
P < 0.05), but greater differences ( ≥ 5%) were observed at 38 sites
representing ten genes. The degree of differential methylation in
PSP was smaller than in cancer, where large differences in
methylation are typically found36 but comparable to other com-
plex disorders such as multiple sclerosis37,38 or Alzheimer’s dis-
ease39–41.
Genes involved in neuronal development and function were
signiﬁcantly overrepresented among the genes differentially
methylated in PSP (Supplementary Data 4 and Supplementary
Data 5). These changes might have cumulative effects on disease
origin and progression.
Two prior studies performed targeted, hypothesis-driven epi-
genetic analyses in DNA extracted from brain tissue and found
differential methylation of MAPT on chromosome 17q21.31 in
PSP patients7,8. Another prior study found differential methyla-
tion in the region of MAPT in peripheral blood DNA of PSP
patients9. This methylation difference was associated with the H1
haplotype of MAPT, which is overrepresented in PSP1,5. In our
epigenome-wide analysis, nine CpG sites within MAPT yielded
signiﬁcantly different methylation values in PSP vs. controls,
which, however, did not hold up to correction for multiple testing
(Supplementary Data 3). Thus, our ﬁndings are not at odds with
these prior reports, but represent a more conservative
interpretation.
Among the 375 genes identiﬁed in our study, differential
methylation was most pronounced at DLX1 that was hyper-
methylated at multiple CpG sites including a CpG island. Its
methylation status differed by up to > 10% between PSP and
controls. The other genes showed altered methylation levels at
one or a few CpG sites only, and methylation differences were
mostly low ( < 2%). The observed hypermethylation of DLX1 in
its 3´region did not alter DLX1 transcription. However, the
amount of the newly detected DLX1AS transcript that overlaps
with parts of exon 3 and with the 3´UTR of DLX1, was sig-
niﬁcantly reduced to 0.64-fold in PSP as compared to controls.
DLX1AS is a likely negative regulator of DLX1 translation by
dimer formation between the sense and antisense RNA42. Con-
sistently, we observed increased expression of DLX1 protein in
gray matter of forebrains in PSP on western blots and by
immunohistochemistry. Interestingly, an enhancer has been
assigned to the 5´region of DLX1AS18. This enhancer appears to
be part of DLX1AS. As such it might be involved in modiﬁcation
of the amount of DLX1 protein in different tissues (e.g., gray vs.
white matter) by controlling the amount of DLX1/DLX1AS RNA
dimer formation. Alternatively, instead of forming a RNA/RNA
dimer, DLX1AS might also form a complex with various proteins
that in turn regulate expression of DLX1. This mode of action has
been shown for DLX6AS/EVF243,44.
DLX1 encodes a homeobox-containing transcription factor. It
is mainly expressed in GABAergic inhibitory interneurons. In
concert with other DLX genes it impacts interneuron develop-
ment and function45–47. This is consistent with our observation of
mainly neuronal expression of DLX1 in single cells in humans,
conﬁrming previously described neuronal speciﬁcity of Dlx1
expression in mice22. Similarly, Dlx1as and DLX1AS are also
predominantly expressed in neurons in both mouse and human.
Interestingly, individual neurons of healthy human cerebral cor-
tex expressed either DLX1 or DLX1AS, but only very few neurons
expressed both DLX1 and DLX1AS, suggesting that expression of
DLX1 and DLX1AS might be regulated in an opposite manner
(Supplementary Fig 4). This interpretation would be consistent
with our cell culture experiments showing increased DLX1AS
expression upon DLX1 silencing and vice versa.
The ﬁnding of differential methylation of various genes within
a putative DLX1 pathway (Fig. 6) further strengthens the notion
of an important role of DLX1 in the etiology of PSP. While
methylation differences were comparatively subtle at most of
these genes, together they might be sufﬁcient to alter the pathway
in a functionally relevant manner in PSP. During normal ageing,
the methylation pattern of cells may change dramatically, without
having apparent functional effects in most cases48,49. In some
instances, however, functionally related genes may become dif-
ferentially methylated and predispose to disease via their inter-
action. Of particular interest is our ﬁnding that the putative DLX1
pathway extends to MAPT. Via this pathway overexpressed DLX1
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might modify protein Tau by increasing its phosphorylation,
which in turn contributes to tangle formation1. In vitro experi-
ments support dependency of MAPT expression on the con-
centration of DLX1/DLX1AS transcripts. Currently, it remains
unclear whether DLX1 inﬂuences MAPT expression directly or
indirectly. Given that we could not conclusively show direct
binding of DLX1 to the MAPT promoter, the effect of DLX1 on
MAPT appears to be more indirect (via the Wnt or the
GABAergic interneuron-related network pathway). Furthermore,
a high-throughput ChIP-sequencing study with enrichment
proﬁles for a large set of factors50 also used an antibody against
DLX1 but did not ﬁnd enrichment at or near the MAPT locus.
Differential methylation of the various genes related to neuronal
development and function might also be a secondary event rather
than the primary cause of disease in PSP. It has been shown, that
DLX1 is essential for survival of adult interneurons in the neo-
cortex46 and in mature retinal cells51. Thus, differential regulation
of DLX1 and interacting genes involved in neuronal development,
differentiation and plasticity, might refer to endogenous repair
mechanisms in neocortical areas affected by PSP52. Consistent
with these ﬁndings we found that siRNA-mediated knock-down
of DLX1 decreases neuronal viability in strNPCs overexpressing
either 3R-Tau or 4R-Tau. Knock-down of DLX1AS rescued cells
from death independent of overexpression of Tau.
In conclusion, we found signiﬁcant methylation differences in
DNA from forebrains of PSP patients as compared to controls.
Differential methylation affected a high percentage of genes
involved in neuronal differentiation and function. Methylation
differences were particularly high at DLX1/DLX1AS that are
expressed in neurons almost exclusively. DLX1 protein was
increased in gray matter of patients´ forebrains and was shown to
negatively affect MAPT expression in vitro. DLX1 may thus
contribute to disease by disturbing the normal function of neu-
rons and might serve as a novel molecular target for the devel-
opment of disease-modifying therapies.
Methods
Brain tissue. The use of human brain tissue for this project was approved by the
ethics committees of the University of Giessen and of the Technical University of
Munich. Brain samples were from patients who had given informed consent before
death.
For the epigenome-wide DNA methylation analysis, postmortem prefrontal
lobe tissue of PSP patients (N= 94, 72 ± 5.3 years of age, N= 54 (57%) male) and
controls without neurological or psychiatric diseases (N= 71, 76 ± 7.9 years of age,
N= 46 (67%) male) was obtained from the CurePSP brain bank, Mayo Clinic,
Jacksonville, Florida and the Victorian Brain Bank, Carlton, Australia. Detailed
information on clinical and neuropathological ﬁndings is given in Supplementary
Data 1. Of the PSP patients, 83 were homozygous and 11 were heterozygous for
allele H1 of MAPT, none were homozygous for the H2 allele. Among the controls,
54 were homozygous for the H1 allele, 14 were heterozygous and 3 were
homozygous for the H2 allele.
For western blot analysis, postmortem gyrus frontalis superior tissue of PSP
patients (N= 8, 71.9 ± 6.3 years of age, N= 5 (63%) male) and controls without
neurological or psychiatric diseases (N= 8, 74.6 ± 7.0 years of age, N= 2 (25%)
male) was obtained from the Ludwig-Maximilians-Universität Munich and the
Hospital Clínic de Barcelona brain banks.
For immunohistochemistry, postmortem gyrus frontalis superior tissue of PSP
patients (N= 24, 72.6 ± 4.8 years of age, N= 18 (75%) male) and controls without
neurological or psychiatric diseases (N= 9, 70.6 ± 9.7 years of age, N= 4 (44%)
male) was obtained from the CurePSP brain bank, Mayo Clinic, Jacksonville,
Florida.
Nucleic acids and PCR. DNA and RNA were extracted from tissue samples by
standard procedures. DNA was prepared using the tissue extraction kit from
Qiagen (Hilden, Germany) and RNA was extracted using the RNeasy Lipid Tissue-
Kit (Qiagen). Genomic DNA was bisulﬁte-converted using the EpiTect Bisulﬁte Kit
(Qiagen). For RT-qPCR, total RNA was converted into cDNA using the
QuantiTec-Reverse-Transcription kit (Qiagen).
For investigation of the brain tissue samples, all primers used for standard PCR
and RT-qPCR were designed using OLIGO Primer analysis software (Vers. 6.41;
Molecular Biology Insights, Inc., Colorado Springs, CO, USA). Primers used for
qPCR are given in Supplementary Table 1. Fluorescence data were compiled using
the CFX384 qPCR system from Bio-Rad (Hercules, CA, USA). Housekeeping genes
EIF4A2 and CYC1 were co-analyzed for normalization of RNA content in each
brain sample53.
Quantiﬁcation of expression differences (fold-expression) was calculated using
the REST-Software-Package-2009 as described elsewhere54.
Expression of the housekeeping genes B2M, EIF4A2, and CYC1 was analyzed
for normalization in cell culture experiments with SH-EP und Ntera2 cells. Stability
values, i.e., coefﬁcient of variation (CV-value) and gene stability value (M-value)
for each housekeeping gene were < 0.25 for CV- and < 0.5 for the M-value. Fold
expression was calculated with the integrated qBase module of the Bio-Rad CFX
Manager 3.1 (3.1.1517.0823) software. Signiﬁcance of expression changes was
evaluated by unpaired two-tailed Student´s t-test.
We have used DNAse treated total-RNA in all RT-qPCR experiments. This
excluded co-ampliﬁcation of DNA that might have contaminated RNA
preparations. Exclusion of DNA co-ampliﬁcation was particularly important for
analysis of exon1-derived RNA of DLX1AS. Exon1 RNA of DLX1AS was analyzed
since this exon was present in all alternative transcripts.
RT-qPCR analyses were performed on RNAs extracted from strNPCs using
SYBR Green Select qPCR Supermix (#4472954, Life Technologies, Carlsbad, USA),
5 ng cDNA synthesized from total RNA, 0.2 μM forward and reverse primers
(primer sequences are given in Supplementary Table 1). qPCR analysis was
performed on a Step One Plus instrument (Thermoﬁsher Scientiﬁc, Carlsbad,
USA). Initial incubation at 50 °C for 2 min and an additional 2 min at 95 °C was
followed by 40 cycles of 15 s at 95 °C and 60 s at 60 °C. Threshold cycle (CT) values
were set within the exponential phase of the PCR. Data were normalized to ﬁve
housekeeping genes: TBP, GPBP1, PPIA, PSMC1, UBQLN2 and the comparative
normalized relative quantity (CNRQ) was used to calculate fold expression
(qBase®, Biogazelle, Belgium). Gene regulation was statistically evaluated by two-
tailed Student’s t-test on the assumption of equal variances.
Array analysis. The Inﬁnium 450k array of Illumina Inc. (San Diego, CA) was
used for methylation analysis. This array analyzes more than 485,000 CpG sites
distributed over the entire genome. Two-hundred nanograms of bisulﬁte-converted
DNA were hybridized to the arrays according to the manufacturer´s instructions.
In order to exclude batch effects, we alternated hybridization of PSP and control
samples. Arrays were scanned on an Illumina iScan platform at the Life & Brain
Center (Bonn/Germany). Array data were evaluated, preprocessed and normalized
using the ChAMP pipeline (V.2.8.1)55,56 with minor modiﬁcations. Speciﬁcally,
raw array data were uploaded to the ChAMP pipeline using the minﬁ option57.
Relative proportions of neuronal and non-neuronal cells in each sample were
estimated based on the raw data applying the compositeCellType= ”DLPFC”
option of estimateCellCounts function of the R Bioconductor minﬁ package58.
Probes with less than three measured beads or a detection P-value > 0.01 as well as
probes interrogating CpGs that fall on or near to a SNP were removed based on
recommendations by Zhou et al.59. Similarly, probes aligning to multiple locations
as deﬁned by Nordlund et al.60 were removed from the analysis. All samples had
more than 99.3% of valid probes, therefore, no samples were removed from the
analysis based on the quality of the data. The sex of each sample was veriﬁed using
an in-house R script based on the DNA methylation proﬁle of the X and Y
chromosomes. One single control sample was not in concordance with the assigned
sex and was excluded from further analysis. Differences between probes due to InfI
and InfII probe usage as well as between samples were normalized using BMIQ61
on the 435,803 remaining probes. Differential methylation was determined using a
modiﬁed version of the champ.dmp function with age, sex, and estimated pro-
portion of non-neuronal cells as covariates in a linear regression analysis based on
the limma package62 adjusting P-values for multiple testing with a Benjamini-
Hochberg correction14. Differentially methylated CpGs were considered signiﬁcant
at adjusted P-values < 0.05. To account for potential confounding owing to genetic
variation, signiﬁcant probes were ﬁltered for signiﬁcant mQTLs in adult prefrontal
cortex using previously published data, which removed three CpGs all of which
associated with GABRA5 (cg01378667, cg03325535, cg10318222) as deﬁned by a
SNP in close proximity to the gene (rs7496866)15.
We computed the exact statistical power for each of the 485,577 probe sets on
the microarray based on the data obtained in our sample by applying the function
pwr.t2n.test of the pwr package of R statistical software. The parameters of this
function are the number of patients and controls, i.e., n= 94 and n= 71,
respectively, as well as the signiﬁcance level of 0.05 and Cohen’s d (effect size). The
effect size is deﬁned by the difference between the means of the group divided by
the pooled standard deviations of the two groups. Given these parameters, a power
of at least 80% is calculated for 14,553 out of the total of 485,577 probes. Of the 717
CpG sites, which were signiﬁcantly differentially methylated in PSP as compared to
controls 664 (92.6%) showed a power of greater than 80% (Supplementary Data 6).
The circle plot was built with hg19 as reference genome using the OmicCircos
R-Package Version 1.4.063 for R version 3.1.364.
Pyrosquencing. Pyrosequencing was done on a Pyromark-Q24 using PyroMark-
Q24 tools and reagents (Qiagen) according to the manufacturer´s protocol. Primers
for pyrosequencing (PCR product and sequencing primer) were designed using
PyroMark-Assaydesign-2.0.1.15 (Qiagen) software. Primer sequences are shown in
Supplementary Table 1. Data were analyzed with the PyroMark-Q24 software.
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Western blot. White and gray matter from the Gyrus frontalis superior of post-
mortem tissue was extracted in ice-cold N-PERTM lysate buffer (#87792, Ther-
moFisher Scientiﬁc, Waltham, MA, USA) using the Dounce homogenizer with
10–20 strokes on ice. Proteins were obtained after removal of cellular debris by
centrifugation at 10.000 rpm for 10 min at 4 °C. Thereafter, 1 × HALTTM protease
inhibitor (#78442, ThermoFisher Scientiﬁc, Waltham, MA, USA) was added to
each supernatant. Protein concentration was determined by Bicinchoninacid assay
(#23225, ThermoFisher Scientiﬁc, Waltham, MA, USA).
Equal amounts of proteins were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis with 4–20% CriterionTM, TGX Stain-freeTM
Protein gels (#5678094, Bio-Rad, Munich, Germany). Molecular weight markers
used were # 830537 and # 830552 (Hessisch Oldendorf, Germany). Thereafter the
protein staining was activated by UV light using the ChemiDoc-XRS system (Bio-
Rad, Munich, Germany). After transfer to immuno-blot polyvinylidene diﬂuoride
(PVDF) membrane (#162–0177, Bio-Rad, Munich, Germany) proteins were ﬁxed
on the membrane with 3.75% paraformaldehyde (PFA) in 1 × PBS at room
temperature (RT) for 15 min. After 3 × 10 min washing steps in 1 × PBS,
membranes were incubated with primary DLX1 antibody (dilution 1:1000,
ab126054, polyclonal rabbit AB, Abcam, CA, UK) for 48 h at 4 °C. (Human Protein
Atlas entry: [https://www.proteinatlas.org/ENSG00000144355-DLX1/tissue]).
Positive bands were detected using HRP-conjugated secondary antibody (dilution
1:5000, ab P0448, polyclonal goat anti rabbit immunoglobulins, afﬁnity isolated,
Agilent, CA, USA) and chemolumina substrate (#170–5061, Clarity™ Western ECL
Blotting Substrate, Bio-Rad, Munich, Germany). Blots were stripped and
hybridized with β-actin antibody overnight (dilution 1:2000, ab 3700, clone
8H10D10, mouse monoclonal β-actin antibody, Cell Signaling Technology, CA,
UK). Positive bands were detected by an HRP-conjugated secondary antibody
(dilution 1:5000, ab P0447 polyclonal goat anti mouse immunoglobulins, afﬁtinity
isolated) and chemoluminescent substrate (see above). Bands were scanned using
the ChemiDoc-XRS system and Image Lab software V.5.1 was applied to
measurement of optical densities (Bio-Rad). Optical densities of anti-DLX1
antibody positive bands were compared to TGX labeled total protein and the
housekeeping protein β-actin. DLX1 antibody was validated in positive and
negative controls, e.g., tissue speciﬁc human neuronal progenitor cells derived from
striatum or protein lysates from the human pancreas.
Aperio methodology. DLX1 immunopositive structures on tissue sections were
quantitatively measured applying Aperio technology (Leica Microsystems Inc.,
Buffalo Grove, IL). Immunostained frontal cortical sections were scanned at 20 ×
magniﬁcation on the ScanScope® AT2 (Leica Biosystems, Wetzlar, Germany). The
tissue sections were annotated using ImageScope (Leica Biosystems) to trace both
gray matter and neighboring white matter along the strait of the gyrus, speciﬁcally
avoiding the depth of the sulcus and rise of the gyrus. Annotated slide ﬁles were
analyzed with a custom-designed color deconvolution algorithm using the eSli-
deManager (Leica Biosystems).
Cell culture experiments. We used Ntera2, SH-EP cells, and strNPCs in our
studies. Ntera2 cells (pluripotent human embryonal carcinoma cells with char-
acteristics of neuroepithelial precursor cells) were applied to overexpression
experiments of DLX1 since intrinsic DLX1 mRNA expression is low. Ntera2 cells
display neuronal characteristics (e.g., differentiation into neurons upon induction
with retinoic acid), grow well under standard cell culture conditions and can be
easily transfected.
SH-EP cells, a human neuroblastoma-derived cell line, were used in
experiments involving DLX1AS overexpression. Endogenous expression of DLX1 is
increased as compared to other cell lines tested. We studied human striatal
neuronal precursor cells (strNPCs) for siRNA experiments since they are
commonly used as proxies of neuronal cells. They are not transformed and thus
lack the malignant phenotype of other cell lines.
Human cell lines SH-EP were grown in RPMI Medium (GibCo) and Ntera-2
(NT2) in DMEM Medium (GibCo), containing 10% fetal calf serum (SIGMA),
Glutamine [2 mM], Penicillin-G [100 U/ml] and Streptomycin [100 µg/ml] at 37 °C
and 5% CO2. (SH-EP and NT2 Cells were provided by the Neuroblastoma Study
Group Cologne, Germany).
A full-length cDNA encoding DLX1 (NM_178120.4) and cDNAs of DLX1AS
transcript variants (tv) 2 (KU179669), 4 (KU179671), 5 (KU197672) and partial
transcript variant 1 (5´part of KU179668 [hg19]chr2:172,958,068–172,958,335
joined with chr2:172,954,669–172,954,850) were PCR-ampliﬁed from fetal brain
mRNA, sequenced and cloned into a pcDNA-3.1-TOPO vector.
Cells were transfected with these constructs or empty vector using Viromer-Red
transfection reagent (Lipocalyx, Germany) and selected in medium containing
G418. Cells were grown in this medium for 14–21 days. They were harvested at a
conﬂuency of 70–80%.
siRNA-mediated knock-down experiments were performed in fetal striatum-
derived human neuronal progenitor cells (srtNPCs)65 using siPOOL-DLX1 siRNA,
siPOOL-DLX1AS and siPOOL non-coding (nc)siRNA (siTOOLs BIOTECH,
Planegg, Germany). Experiments were repeated three times. Transfection of
siRNA-Pools was done with Lipofectamine® RNAiMAX reagent (#13778150,
ThermoFisher Scientiﬁc, Carlsbad, USA) according to the manufacturer’s protocol
at a ﬁnal concentration of 5 nM. Cells were harvested and lysates prepared after
6 days of culture.
ATP Assay was performed according to standard procedures27. strNPCs were
transfected with siPOOL-DLX1, siPOOL-DLX1AS or siPOOL-ntsiRNA on day one
of culture. After 48 h Lentiviruses overexpressing either mCherry, MAPT3R or
MAPT4R66,67 were added to the cells. Cells were harvested 6 days after onset of
culture and ATP assays were performed using ViaLight™ plus kit (LT07-221, Lonza,
Germany).
Literature mining and pathway analysis. Using Network Builder of the Pathway
Studio software (Elsevier) version 12.0.1.5 we generated a literature-derived net-
work that was based on text mining for direct interactions between signiﬁcantly
differentially methylated input genes. The input dataset comprised genes adjacent
to the 717 genomic positions (CpG sites) found to signiﬁcantly differ in methy-
lation between PSP patients and controls. We only analyzed those genes by Net-
work Builder that are known to be expressed in the telencephalon and in
interneurons. The GeneRanker program (Genomatix) was used for analysis of
association of differentially methylated genes in tissues (Supplementary Data 5)67.
The literature-derived network was curated and extended by manual literature
searches as well as by in silico prediction of transcription factor binding sites
applying the MatInspector program (Genomatix).
The complete set of differentially methylated genes was further explored using
the Pathway Studio software for enrichment in the category “biological process” of
the Gene Ontology by applying Fisher’s exact test. P-values were corrected for
multiple testing by Benjamini and Hochberg14.
Single-cell analysis. We downloaded data on single cells from GEO and processed
them according to the recommendations detailed in [GSE67835]22.
We applied the program Prinseq (-min_len 30) to remove very short non-
speciﬁc reads. Prinseq also trimmed both ends of the reads in order to eliminate
5´duplicates (-trim_left 10) and to remove low quality 3´ends (-trim_qual_right
25). Furthermore Prinseq ﬁltered reads of low complexity (-lc_method entropy
/-lc_threshold 65). The program FASTQC was used to identify sequences that are
overrepresented (adapter) in order to exclude them from further analysis. We used
the Prinseq tool to remove orphan pairs less than 30 bp in length followed by
removal of nextera adapters using Trim Galore (--stringency 1).
Reads were aligned to the hg19 genome with STAR using the following options
(-outFilterType BySJout/--outFilterMultimapNmax 20/--alignSJoverhangMin 8/--
alignSJDBoverhangMin 1 /--outFilterMismatchNmax 999/--
outFilterMismatchNoverLmax 0.04/--alignIntronMin 20 /--alignIntronMax
1000000 /--alignMatesGapMax 1000000 /--outSAMstrandField intronMotif).
Aligned reads were converted to counts for each gene using HTSeq (-m
intersection-nonempty /-s no). The human Ensembl General Feature Format
(GTF) annotation ﬁle (version 2013–09) necessary for HTSeq was extended by
DLX1AS splice variants represented by the following Genbank identiﬁer
KU179668.1, KU179669.1, KU179670.1, KU179671.1, and KU179672.1. For all
analyses Genome_build hg19 was used. Finally, counts were converted to FPKM
(Fragments per kilobase of transcript sequence per million mapped fragments)
values.
Out of 466 available single-cell datasets, we selected 251 datasets that represent
speciﬁc cortical cell types (astrocytes, microglia, oligodenrocytes, endothelia,
neurons, oligodendrocyte precursor cells, see [https://www.ncbi.nlm.nih.gov/
Traces/study/?acc= SRP057196]). Hybrid cells and fetal quiescent cells were not
considered.
In silico promoter analysis. All sequences analyzed are from the promoter
sequence retrieval database EIDorado 12–2016 (Genomatix) that is based on NCBI
build GRCh38. The following Genomatix / Entrez Gene identiﬁers for MAPT were
used: GXP_10577 / 4137 (human), GXP_7225047 / 574327 (rhesus_monkey),
GXP_5397266 / 100054638 (horse), GXP_3861378 / 281296 (cow). Promoter
sequences of MAPT from four mammalian species were aligned using the DiAlign
TF program of the Genomatix software suite GEMS Launcher in order to evaluate
overall promoter similarity and to identify DLX1-binding sites. The corresponding
position weight matrices V$DLX1.01 and V$DLX1.02 were applied to promoter
analysis according to the Matrix Family Library Version 10.0 (October 2016).
Binding sites were considered conserved if promoter sequences could be aligned in
the region of the DLX1-binding site using the DiAlign TF program.
Statistics. Statistical tests were performed within the R computing environment64
[http://www.r-project.org]. In order to calculate Pearson’s product moment cor-
relation the R function cor.test was used by setting alternative= ”two-sided” and
method= ”pearson”. We applied the function t.test to two sample t-tests with
Welchs’s correction and the arguments paired= ”FALSE”, alternative= ”two.
sided” and var.equal= ”FALSE”. Mann–Whitney tests were performed by
using the R function wilcox.test in conjunction with paired= ”FALSE” and alter-
native= ”two-sided”.
Test of normality according to Kolmogorov–Smirnov was applied separately to
CpG-control and CpG-PSP samples for one speciﬁc gene from pyrosequencing
analysis. If one of both tests was signiﬁcant the corresponding dataset was deﬁned
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as not normally distributed. If only one of all CpG samples for a speciﬁc gene are
not normally distributed the unpaired t-test with Welch’s correction was
performed otherwise the Mann–Whitney test. In case of the densitometry of
DLX1-immunoreactivity experiment the Mann–Whitney test was used because the
corresponding datasets were not normal distributed according to
Kolmogorov–Smirnov.
In general, P < 0.05 was considered signiﬁcant. For bar plots the mean ± SEM
(standard error of the mean) is given unless indicated otherwise.
Whenever multiple tests were computed e.g., for enrichment analyses of gene
occurrences in pathways these P-values were corrected according to Benjamini-
Hochberg or according to other appropriate methods, which are given in the
corresponding subsections for array and pathway analyses.
Data availability. Normalized and raw BeadChipArray data have been deposited
in NCBI- Gene Expression Omnibus (GEO) with the accession code GSE75704.
DLX1AS transcript variants have been uploaded to NCBI under accession
numbers KU179668, KU179669, KU179670, KU179671, and KU179672.
All other data are available within the paper and its associated supplementary
material or upon reasonable request from the corresponding authors.
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